ALE P02
Alternative Names: ALE-P02; ALE.P02Latest Information Update: 18 Sep 2023
At a glance
- Originator Alentis Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Claudin 1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Jul 2023 Preclinical trials in Cancer in Switzerland (Parenteral), prior to July 2023 (Alentis Therapeutics pipeline, July 2023)